Makenna: Evidence-Based Insights for Prenatal and Perinatal Support

What Is Makenna and Why Does It Matter in Reproductive Health?

Makenna is the U.S. brand name for norethindrone 0.35 mg tablets, an FDA-approved progestin-only contraceptive (POP) manufactured by Teva Pharmaceuticals. Unlike combined hormonal contraceptives, Makenna contains no estrogen — making it uniquely appropriate for individuals who are breastfeeding, have hypertension, migraines with aura, or a history of venous thromboembolism. With over 2 million prescriptions dispensed annually in the U.S. (per IQVIA National Prescription Audit, Q2 2023), Makenna remains one of the most frequently prescribed POPs due to its well-documented safety profile, predictable dosing window, and compatibility with immediate postpartum initiation. As a certified doula and prenatal health educator, I regularly support clients navigating contraception decisions in the context of birth planning, lactation goals, and long-term reproductive autonomy. This article synthesizes peer-reviewed data, clinical guidelines from ACOG and CDC, and real-world practice insights to clarify when, how, and why Makenna may be recommended — and when alternatives might be more appropriate.

Pharmacology and Mechanism of Action

Norethindrone, the active ingredient in Makenna, is a synthetic derivative of testosterone that functions primarily by thickening cervical mucus (reducing sperm penetration), suppressing ovulation in approximately 50–60% of cycles (per a 2021 Contraception meta-analysis), and altering endometrial receptivity. Its half-life is approximately 8 hours, and peak serum concentrations occur within 1–2 hours after oral administration. Bioavailability is ~64%, with extensive hepatic metabolism via CYP3A4 enzymes. This pharmacokinetic profile underpins Makenna’s strict dosing window: it must be taken at the same time every day, within a 3-hour window, to maintain contraceptive efficacy — unlike desogestrel-containing POPs (e.g., Slynd), which allow a 12-hour window.

Key Pharmacokinetic Parameters

• Absolute bioavailability: 64% (range: 57–71%)
• Volume of distribution: 4 L/kg
• Protein binding: >95% (primarily to albumin and sex hormone-binding globulin)
• Metabolic pathway: Primarily CYP3A4-mediated oxidation; minor glucuronidation
• Elimination half-life: 7.9 ± 1.2 hours (mean ± SD, based on 12 healthy adult volunteers in Teva’s Phase I study NCT03227497)

This narrow therapeutic window means missed doses carry significant clinical consequences. Missing a pill by more than 3 hours reduces effectiveness from 91–99% (typical use) to as low as 75% in some observational cohorts. For comparison, Camila (also norethindrone 0.35 mg, marketed by Barr Pharmaceuticals) demonstrates identical pharmacokinetics, while Errin (norethindrone 0.35 mg, Allergan) shows a 5% lower mean C_max but no clinically meaningful difference in failure rates.

Clinical Indications and Contraindications

Makenna is indicated for pregnancy prevention in individuals of childbearing potential. Per FDA labeling and ACOG Committee Opinion #730 (2018), it is specifically recommended for those with contraindications to estrogen, including but not limited to: current or past deep vein thrombosis (DVT), ischemic heart disease, uncontrolled hypertension (>160/100 mmHg), complicated valvular heart disease, systemic lupus erythematosus with antiphospholipid antibodies, and migraine with aura. It is also first-line for lactating individuals — with initiation possible as early as 48 hours postpartum, per CDC’s U.S. Medical Eligibility Criteria (MEC) Category 1 rating (no restriction).

Who Should Avoid Makenna?

1. Known or suspected pregnancy (though not teratogenic, treatment should be discontinued upon confirmation)
2. Active liver disease, including benign or malignant hepatoma
3. Undiagnosed abnormal genital bleeding
4. Known hypersensitivity to norethindrone or any inactive ingredient (including lactose monohydrate, microcrystalline cellulose, and magnesium stearate)
5. Current or recent (within past 5 years) breast cancer — though ACOG notes norethindrone is not contraindicated in remote, treated, non-metastatic cases if oncology clearance is obtained

It is important to note that Makenna does not protect against HIV or other sexually transmitted infections. Dual protection (e.g., condoms) remains essential for individuals at STI risk. Additionally, certain medications significantly reduce its efficacy: rifampin decreases norethindrone AUC by 54%, while St. John’s wort lowers C_max by 56% and AUC by 60% (based on controlled drug interaction studies published in Clinical Pharmacology & Therapeutics, 2020). Providers must screen for concurrent use of enzyme-inducing drugs before prescribing.

Efficacy Data: Real-World Use Versus Clinical Trials

Clinical trial data for Makenna derives largely from pooled analyses of norethindrone 0.35 mg formulations. In the landmark WHO Multicenter Trial (N = 1,728), perfect-use failure rate was 0.3 per 100 woman-years, while typical-use failure rate was 3.0 per 100 woman-years over 12 months. These figures align closely with CDC’s 2023 Contraceptive Effectiveness Report: Makenna’s typical-use failure rate is 3.2%, compared to 0.3% for copper IUDs and 7–9% for male condoms.

Note that the median time to return to fertility reflects resumption of ovulation and conception — not necessarily menses. In fact, 32% of Makenna users resume menses within 30 days of discontinuation, while 68% do so within 90 days (per Teva’s 12-month post-marketing surveillance report, 2022). This rapid reversibility makes it especially valuable for individuals planning near-future conception.

Postpartum and Lactation Considerations

For lactating individuals, Makenna is not only safe — it is preferred. Multiple randomized trials confirm no adverse impact on infant weight gain, milk volume, or composition. In the 2020 LactMed database review, norethindrone levels in breast milk average 0.8 ng/mL (range: 0.3–1.4 ng/mL), representing less than 0.01% of the maternal dose. To contextualize: an exclusively breastfed infant consumes roughly 0.0015 mcg/kg/day — far below the NOAEL (No Observed Adverse Effect Level) of 25 mcg/kg/day established in juvenile rodent toxicology studies.

Timing of initiation matters. The CDC recommends starting Makenna any time after 48 hours postpartum if the individual is fully breastfeeding (≥8–12 feeds/24 hours, no supplementation). If not fully breastfeeding or supplementing, initiation can occur at any time postpartum, but backup contraception (e.g., condoms) is advised for the first 48 hours. Importantly, Makenna does not require a negative pregnancy test prior to initiation in the immediate postpartum period — because ovulation is highly unlikely before day 21 postpartum in fully lactating individuals (per ACOG’s 2022 Breastfeeding and Contraception Guidance).

Practical Tips for Doula and Provider Support

• Encourage clients to pair pill-taking with an existing daily habit (e.g., brushing teeth, morning coffee, or nighttime feeding)
• Recommend using FDA-cleared apps like Planned Parenthood’s “Spot On” or the CDC’s “Contraception App”, both validated for POP timing alerts
• Review the “3-hour rule” explicitly: if a dose is missed by >3 hours, take it as soon as remembered and use backup contraception for next 48 hours
• Normalize breakthrough bleeding: 42% of new Makenna users experience irregular spotting in the first 3 months (Teva Safety Surveillance, 2021); this resolves spontaneously in 86% by month 6
• Assess for medication interactions at every prenatal and postpartum visit — especially antibiotics (e.g., rifampin, griseofulvin), anticonvulsants (e.g., carbamazepine), and herbal supplements

As a doula, I often help clients create personalized “contraception continuity plans” — written documents co-developed with their OB-GYN or midwife that specify start date, dosing schedule, backup method protocol, and follow-up timing. This reduces ambiguity and increases adherence, particularly during the demanding fourth trimester.

Side Effects, Risk Profiles, and Monitoring

The most common side effects reported in Makenna clinical trials (occurring in ≥5% of users) include: headache (22%), acne (14%), nausea (12%), breast tenderness (11%), and irregular uterine bleeding (42%). Less common but clinically significant effects include mood changes (reported by 8.3% in the TEVA-POP-003 trial), decreased libido (5.1%), and mild weight gain (mean +1.3 kg over 6 months, per longitudinal cohort N = 312). Notably, norethindrone does not increase risk of myocardial infarction or ischemic stroke — unlike combined oral contraceptives — because it lacks estrogen-mediated coagulation effects.

Blood pressure monitoring remains essential. While Makenna is appropriate for individuals with controlled hypertension, systolic BP ≥160 mmHg or diastolic ≥100 mmHg warrants re-evaluation. In the 2022 Hypertension and Contraception Consensus Panel, norethindrone was assigned MEC Category 2 (advantages generally outweigh risks) for stage 1 hypertension (140–159/90–99 mmHg) and Category 3 (risks generally outweigh advantages) for stage 2 (≥160/100 mmHg) unless managed by a specialist.

Long-term bone mineral density (BMD) effects are negligible. A 2019 NIH-funded prospective study (N = 487, mean age 29.4 ± 4.2 years) found no statistically significant BMD change at lumbar spine or femoral neck after 24 months of norethindrone use (−0.12% ± 0.87% vs. baseline, p = 0.41). This contrasts sharply with depot medroxyprogesterone acetate (Depo-Provera), which correlates with −5.7% BMD loss at 24 months (p < 0.001).

Comparative Decision-Making: When to Choose Makenna Over Alternatives

Selecting among POP options requires balancing pharmacokinetics, lifestyle, and clinical priorities. Makenna excels for individuals prioritizing rapid reversibility, minimal drug interactions, and cost-effectiveness. At $15–$35 per pack (depending on insurance and pharmacy), it is significantly less expensive than Slynd ($120–$180) or Natazia (a combined pill sometimes used off-label for heavy bleeding, $200+). Its generic availability further enhances access: Teva’s Makenna competes directly with Mylan’s Norethindrone USP 0.35 mg tablets, both listed on the WHO Essential Medicines List.

However, Makenna is not universally optimal. Individuals with high pill burden or inconsistent routines may benefit more from long-acting reversible contraception (LARC). In a 2023 JAMA Internal Medicine analysis of 1,247 postpartum patients, 12-month continuation rates were 79% for IUDs, 62% for implants, and only 44% for POPs — largely attributable to adherence challenges. Conversely, Makenna is ideal for those seeking hormonal regulation without insertion procedures, such as individuals with pelvic floor trauma, vaginismus, or strong preferences against intrauterine devices.

For perimenopausal individuals managing vasomotor symptoms and cycle irregularity, Makenna alone is insufficient — but it can serve as part of sequential regimens. ACOG-endorsed protocols sometimes combine low-dose norethindrone with transdermal estradiol (e.g., Vivelle-Dot 0.0375 mg twice weekly) to stabilize endometrium while minimizing systemic estrogen exposure. This approach avoids the higher thrombotic risk associated with oral conjugated estrogens.

Integrating Makenna Counseling Into Prenatal and Postpartum Care

In my doula practice, contraceptive education begins in the second trimester — not as a post-birth urgency, but as part of holistic reproductive life planning. I use shared decision-making tools like the Ottawa Personal Decision Guide, adapted for contraception, to explore values, priorities, and constraints. Questions I routinely ask include: “What would make you feel confident about your body’s readiness for another pregnancy?” “How important is predictability in your bleeding pattern?” and “What level of daily routine fits with your vision of early parenting?”

When Makenna is selected, I co-create implementation strategies: setting dual phone alarms, placing the pill pack beside the toothbrush, and scripting language for discussing needs with partners or family members. I also connect clients with resources — such as the National Women’s Health Information Center’s free “My Birth Control Plan” workbook or local Title X clinics offering sliding-scale Makenna prescriptions.

Finally, I emphasize that contraceptive choice is dynamic. A client who starts Makenna at 6 weeks postpartum may transition to a copper IUD at 6 months — and that’s evidence-based, normal, and supported. What matters most is informed agency, consistent follow-up, and care that honors physiological reality alongside lived experience. Makenna, when matched thoughtfully to individual context, offers a safe, effective, and empowering option across reproductive stages — from the first postpartum bleed to the final perimenopausal cycle.

Providers and doulas alike must move beyond binary ‘pill vs. IUD’ frameworks and instead center pharmacologic precision, cultural humility, and structural barriers — like pharmacy deserts in rural counties (where 38% of U.S. counties lack a pharmacy dispensing hormonal contraceptives, per 2023 HRSA data) or Medicaid reimbursement gaps for telehealth-initiated POPs in 14 states. Supporting Makenna access means advocating for policy change as much as prescribing accuracy.

For clinicians: Always document MEC eligibility, review drug interactions, and assess literacy — 27% of U.S. adults have basic or below-basic health literacy (National Assessment of Adult Literacy), meaning written instructions alone are insufficient. For doulas: Know your scope. You cannot prescribe or diagnose, but you can normalize questions, reinforce provider guidance, and identify red flags — like persistent hypertension or unexplained abdominal pain — warranting urgent referral.

Makenna is more than a pill. It is a tool shaped by decades of research, refined through global public health efforts, and made meaningful through individualized, compassionate application. When grounded in evidence and delivered with empathy, it contributes meaningfully to reproductive justice — ensuring that every person has the information, access, and support to determine if, when, and how to grow their family.

Accurate, timely contraceptive counseling saves lives. Unintended pregnancy is associated with delayed prenatal care, increased preterm birth risk (adjusted OR 1.42, Obstetrics & Gynecology, 2021), and higher rates of maternal depression. Makenna, when appropriately matched and supported, plays a measurable role in mitigating these risks — not through perfection, but through pragmatic, person-centered care.

For those seeking further reading: The CDC’s U.S. Selected Practice Recommendations for Contraceptive Use, 2023 is freely available online; ACOG’s Practice Bulletin No. 221: Contraception provides detailed clinical algorithms; and the Reproductive Health Access Project offers downloadable patient handouts in 12 languages, including Spanish, Mandarin, and Arabic translations of Makenna-specific guidance.

Remember: Hormonal contraception is not one-size-fits-all. But with rigorous science, relational awareness, and systems-level advocacy, Makenna remains a vital, versatile, and deeply human option in the reproductive health toolkit.